AbCelex licenses NRC platform technology

Guest Contributor
May 2, 2011

Toronto's AbCelex Technologies Inc has signed an exclusive worldwide licensing agreement with the National Research Council's Institute for Biological Sciences to access its Pentabody platform technology. The privately-held firm will pay NRC an upfront payment, milestone payments and royalties based on future product sales for the technology, which will be used for all of its vitro clinical diagnostic applications. AbCelex develops products for the rapid diagnosis of a wide range of disease-associated biomolecules. www.abcelex.com….


Other News






Events For Leaders in
Science, Tech, Innovation, and Policy


Discuss and learn from those in the know at our virtual and in-person events.



See Upcoming Events










You have 1 free article remaining.
Don't miss out - start your free trial today.

Start your FREE trial    Already a member? Log in






Top

By using this website, you agree to our use of cookies. We use cookies to provide you with a great experience and to help our website run effectively in accordance with our Privacy Policy and Terms of Service.